Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Aurobindo Pharma Plunges 3%; BSE HEALTHCARE Index Down 0.9%
Tue, 5 Nov 12:37

Aurobindo Pharma Plunges 3%; BSE HEALTHCARE Index Down 0.9%Image source: DNY59/www.istockphoto.com

Aurobindo Pharma share price has plunged 3% and is presently trading at Rs 1,361.5.

Meanwhile, the BSE HEALTHCARE index is at 43,468.1 (down 0.9%).

Among the top losers in the BSE HEALTHCARE index today are Lupin (down 3.6%) and FORTIS HEALTHCARE (down 3.6%).

GLAND PHARMA (up 11.9%) and Procter & Gamble Health (up 6.9%) are among the top gainers today.

Over the last one year, Aurobindo Pharma has moved up from Rs 858.9 to Rs 1,361.5, registering a gain of Rs 502.6 (up 58.5%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,350.0 to 43,468.1, registering a gain of 58.9% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 228.0%), SUVEN PHARMACEUTICALS (up 132.5%) and Glenmark Pharma (up 123.8%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 78,423.7 (down 0.5%).

The top losers among the BSE Sensex today are MUNDRA PORT & SEZ (down 3.2%) and Bajaj Finance (down 1.6%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.

In the meantime, NSE Nifty is at 23,889.1 (down 0.4%). HDFC LIFE INSURANCE and MUNDRA PORT & SEZ are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 63,591.3 to 78,423.7, registering a gain of 14,832.4 points (up 23.3%).

Aurobindo Pharma Financial Update...

Aurobindo Pharma net profit grew 60.6% YoY to Rs 9,196 million for the quarter ended June 2024, compared to a profit of Rs 5,725 million a year ago. Net sales rose 10.5% to Rs 75,670 million during the period as against Rs 68,505 million in April-June 2023.

For the year ended March 2024, Aurobindo Pharma reported 64.4% increase in net profit to Rs 31,690 million compared to net profit of Rs 19,277 million during FY23. Revenue of the company grew 16.7% to Rs 290,019 million during FY24.

The current Price to earnings ratio of Aurobindo Pharma, based on rolling 12 month earnings, stands at 22.4.


Equitymaster requests your view! Post a comment on "Aurobindo Pharma Plunges 3%; BSE HEALTHCARE Index Down 0.9%". Click here!